$MCUJF

Medicure Inc. (TSXV:MPH, OTC PINK:MCUJF) completed patient enrollment in its MEND-PNPO Phase 3 trial for MC-1, a treatment for PNPO deficiency. The study enrolled 10 patients, meeting its target. MC-1 has received Rare Pediatric Disease, Orphan Drug, and Fast Track designations from the FDA and EMA. Medicure aims to submit an NDA for MC-1, potentially receiving a Priority Review Voucher upon approval.

Medicure Inc. (TSXV:MPH, OTC PINK:MCUJF) presented data from its MEND-PNPO Phase 3 study at the 16th European Epilepsy Congress. The study evaluates MC-1 for treating PNPO deficiency, a rare neurometabolic disorder. Nine patients have been enrolled, with three completing the one-year study. Medicure aims to enroll about 10 patients. MC-1 is not FDA-approved. The company will also present the study at North American meetings later this year.

MEDICURE INC (MCUJF) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 2-1250 Waverley Street Winnipeg, Manitoba, Canada R3T 6C6 Phone: 204-487-7412 Fax: 204-488-9823 MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2026 AND SCHEDULES AUGUST 17, 2026 CONFERENCE CALL WINNIPEG, CANADA – (August 14, 2026) Medicure Inc. (" Medi

Medicure Inc. (TSXV:MPH, OTC Pink:MCUJF) reported Q2 2026 results for the quarter ended June 30, 2026. Total net revenue rose to C$7.4M from C$6.7M, driven by ZYPITAMAG (C$2.1M vs C$1.7M) and pharmacy segment revenue (C$5.9M vs C$4.2M). AGGRASTAT fell to C$661K. Net loss was C$1.4M (C$0.14/share). Cash was C$1.8M. Conference call set for Aug 17, 2026.

Medicure Inc. (TSXV:MPH; OTC PINK:MCUJF) said CFO Haaris Uddin resigned effective July 24, 2026. James Kinley, previously CFO (2011–2021) and a board member, was named interim CFO and will take over when Uddin departs. The company did not cite financial figures.